Prof. Paolo DELLABONA
Paolo Dellabona graduated in medicine and obtained a Ph.D. in medical genetics from the University of Torino. He is currently joint-head with Giulia Casorati of the Experimental Immunology Unit and Coordinator of the Program of Cancer Immunology and Immuno-Biotherapy at the San Raffaele Scientific Institute in Milano. His main scientific interest concerns the understanding of the development and anti-tumor functions of CD1-restricted T lymphocytes, with a particular focus on NKT cells, a subset of T lymphocytes displaying innate effector functions.
Prof. Thomas GAJEWSKI
Dr. Thomas Gajewski carries out translational research with a focus on cancer immunology. He directs the Melanoma Oncology clinic, is Leader of the Immunology and Cancer Program, and oversees the Human Immunologic Monitoring (HIM)/cGMP Core Facility of the Comprehensive Cancer Center at the University of Chicago. His work focuses on understanding fundamental aspects of immune regulation, applying this knowledge towards studies of anti-tumor immunity, and carrying out novel immunotherapy trials in cancer patients with an emphasis on melanoma. He has published more than 200 papers, has served on multiple grant review committees and editorial boards, is past president of the Society for Immunotherapy of Cancer, has served on the program committees for ASCO and AACR, and is a founding editor of the Journal for Immunotherapy of Cancer. A major focus of current efforts integrates genomic techniques to understand mechanisms of success versus failure of immunotherapies in patients, including a role of the commensal microbiota.
Prof. Pierre COULIE
Pierre G. Coulie, MD PhD, born in Brussels in 1957, is Full Professor at the Faculty of Medicine of the Université catholique de Louvain, located in Brussels, where he teaches immunology. He worked with Prof. Jacques Van Snick on murine rheumatoid factor and cytokines. In 1988 he joined the group of Prof. Thierry Boon and switched to human immunology. Investigator at the Brussels branch of the Ludwig Institute for Cancer Research from 1989 to 1995, he made important contibutions to the identification of human tumor-specific antigens recognized by T lymphocytes. Pursuing his collaboration with the teams of the Ludwig Institute, he is primarily interested in human anti-tumor immunology in the context of therapeutic vaccination with tumor-specific antigens. His current work is focused on the mechanisms of the tumor regressions that are observed in some vaccinated cancer patients, in order to improve the clinical efficacy of these new and remarkably non-toxic cancer treatments.
Prof. Jonathan BROMBERG
Jonathan Bromberg received his MD and PhD degrees from Harvard University (1983), General Surgery Training at the University of Washington (1988), and Transplant Surgery Training at the University of Pennsylvania (1990). He is currently Professor of Surgery and Microbiology and Immunology, and Chief of the Division of Transplantation, at the University of Maryland School of Medicine in Baltimore, Maryland, USA. His clinical interests are in kidney and pancreas transplantation. His research interests are in the migration and trafficking of T cells to secondary lymphoid organs, with a particular focus on suppressive regulatory T cells and their interaction with specific microdomains in the lymph node which determine T cell fate and tolerance.
Prof. Megan SYKES
Dr. Sykes joined Columbia University in April, 2010 after spending 19 years at Massachusetts General Hospital/Harvard Medical School, where she was the Harold and Ellen Danser Professor of Surgery and Professor of Medicine (Immunology). Dr. Sykes’ research career, during which she has published 388 papers and book chapters, has been in the areas of hematopoietic cell transplantation, achievement of graft-versus-leukemia effects without GVHD, organ allograft tolerance induction and xenotransplantation. Dr. Sykes has developed novel strategies for achieving graft-versus-tumor effects without graft-versus-host disease following hematopoietic cell transplantation (HCT). She developed an approach that has been evaluated in clinical trials of non-myeloablative haploidentical HCT whose safety and efficacy allowed trials of HCT for the induction of organ allograft tolerance, with the first intentional achievements of this outcome. Dr. Sykes has dissected the tolerance mechanisms and pioneered minimal conditioning approaches for using HCT to achieve allograft and xenograft tolerance and to reverse the autoimmunity of Type 1 diabetes.
Prof. Hans Dieter VOLK
H.D. Volk borned in 1953. He is Director of the Inst.Med.Immunology, Charité, Director of the Berlin-Brandenburg Center for Regerative Therapies (BCRT) and Deputy Speaker of the Berlin-Brandenburg School for Regenerative Therapies (BSRT) –DFG Graduate School. He published more than 50 patents and is PI or at the steering committees of several collaborative research projects as : Adoptive T cell therapy TR 36 (DFG, 2009),Suppression of undesired immune reaction SFB 650 (DFG, 2013), BioDrIm (EU, 2012), The One Study (EU, 2010), BSRT Graduate School (DFG, 2008), TCR Sequences (IBB, 2010). In 2008, he obtained W3 professorship on Immunology and Regeneration, Charité, HUB.
Prof. Marc BONNEVILLE
Marc Bonneville, (53), D.V.M. and CNRS research director, is currently the director of the Immunology department of the INSERM Cancer Research Center Nantes / Angers (France). Marc started to work in 1983 on transplantation immunology in Nantes (France), and then switched from 1987 to 1989 to upstream immunological issues dealing with mouse cellular immune responses during his postdoctoral training in S. Tonegawa’s laboratory (MIT, Boston). Since 1990 he has been heading a research group working on human cellular immune responses in various physiopathological contexts, with a main focus on so-called « transitional immunity » mediated by gd and NKT cells on the one hand, and virus-specific conventional T cell responses on the other hand. Together with 5 other scientists, he founded in 1999 a biotech company (Innate Pharma SA) that has been developing new immunotherapeutic approaches targeting innate lymphocytes (gd T and NK cells) in the field of infectiology and oncology. Marc Bonneville has authored around 200 scientific papers and 8 patents. He has received several awards and prizes (Bronze and Silver CNRS medal, Halpern and LNCC prizes, …). He has been involved in more than 20 scientific councils and committees and has been an advisor of the INSERM General Director in the field of immunology and biotherapies from 2000 to 2007. As of October 2013, Marc Bonneville has taken up the position of vice-president in charge of the scientific and medical affairs of Institut Merieux, a company dedicated to the development of diagnostic and therapeutic tools in the fields of infectious diseases, cancer and food safety.